|
1
|
Vaux DL: In defense of the somatic
mutation theory of cancer. Bioessays. 33:341–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sonnenschein C and Soto AM: Somatic
mutation theory of carcinogenesis: Why it should be dropped and
replaced. Mol Carcinog. 29:205–211. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soto AM and Sonnenschein C: The tissue
organization field theory of cancer: a testable replacement for the
somatic mutation theory. Bioessays. 33:332–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duesberg P and Rasnick D: Aneuploidy, the
somatic mutation that makes cancer a species of its own. Cell Motil
Cytoskeleton. 47:81–107. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang LJ, Li H, Zhang LY, et al:
Metastasis: inherent vs acquired phenotype. Med Hypotheses.
74:874–876. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weinberg RA: Mechanisms of malignant
progression. Carcinogenesis. 29:1092–1095. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tarin D, Thompson EW and Newgreen DF: The
fallacy of epithelial mesenchymal transition in neoplasia. Cancer
Res. 65:59962005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Suzuki M and Tarin D: Gene expression
profiling of human lymph node metastases and matched primary breast
carcinomas: clinical implications. Mol Oncol. 1:172–180. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weinberg RA: Is metastasis predetermined?
Mol Oncol. 1:263–264, 265–266. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lipponen P, Aaltomaa S, Kosma VM and
Syrjanen K: Apoptosis in breast cancer as related to
histopathological characteristics and prognosis. Eur J Cancer 30A.
2068–2073. 1994. View Article : Google Scholar
|
|
12
|
Lipponen PK and Aaltomaa S: Apoptosis in
bladder cancer as related to standard prognostic factors and
prognosis. J Pathol. 173:333–339. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lipponen P: Apoptosis in breast cancer:
relationship with other pathological parameters. Endocr Relat
Cancer. 6:13–16. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nishimura R, Nagao K, Miyayama H, et al:
Apoptosis in breast cancer and its relationship to
clinicopathological characteristics and prognosis. J Surg Oncol.
71:226–234. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sinicrope FA, Hart J, Hsu HA, Lemoine M,
Michelassi F and Stephens LC: Apoptotic and mitotic indices predict
survival rates in lymph node-negative colon carcinomas. Clin Cancer
Res. 5:1793–1804. 1999.PubMed/NCBI
|
|
16
|
Lee KH, Im SA, Oh DY, et al: Prognostic
significance of bcl-2 expression in stage III breast cancer
patients who had received doxorubicin and cyclophosphamide followed
by paclitaxel as adjuvant chemotherapy. BMC Cancer. 7:632007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ali HR, Dawson SJ, Blows FM, et al: A
Ki67/BCL2 index based on immunohistochemistry is highly prognostic
in ER-positive breast cancer. J Pathol. 226:97–107. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Callagy GM, Pharoah PD, Pinder SE, et al:
Bcl-2 is a prognostic marker in breast cancer independently of the
Nottingham prognostic index. Clin Cancer Res. 12:2468–2475. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Callagy GM, Webber MJ, Pharoah PD and
Caldas C: Meta-analysis confirms BCL2 is an independent prognostic
marker in breast cancer. Bmc Cancer. 8:1532008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rolland P, Spendlove I, Madjd Z, et al:
The p53 positive Bcl-2 negative phenotype is an independent marker
of prognosis in breast cancer. Int J Cancer. 120:1311–1317. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Poincloux L, Durando X, Seitz JF, et al:
Loss of Bcl-2 expression in colon cancer: a prognostic factor for
recurrence in stage II colon cancer. Surg Oncol. 18:357–365. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sinicrope FA, Hart J, Michelassi F and Lee
JJ: Prognostic value of bcl-2 oncoprotein expression in stage II
colon carcinoma. Clin Cancer Res. 1:1103–1110. 1995.PubMed/NCBI
|
|
23
|
Tomita M, Matsuzaki Y, Edagawa M, Shimizu
T, Hara M and Onitsuka T: Prognostic significance of bcl-2
expression in resected pN2 non-small cell lung cancer. Eur J Surg
Oncol. 29:654–657. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
MacherGoeppinger S, Bermejo JL, Wagener N,
et al: Expression and prognostic relevance of the death receptor
CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett. 301:203–211.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ugurel S, Rappl G, Tilgen W and Reinhold
U: Increased soluble CD95 (sFas/CD95) serum level correlates with
poor prognosis in melanoma patients. Clin Cancer Res. 7:1282–1286.
2001.PubMed/NCBI
|
|
26
|
Partridge L, Gems D and Withers DJ: Sex
and death: what is the connection? Cell. 120:461–472. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Knowlton K, Mancini M, Creason S, Morales
C, Hockenbery D and Anderson BO: Bcl-2 slows in vitro breast cancer
growth despite its antiapoptotic effect. J Surg Res. 76:22–26.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pietenpol JA, Papadopoulos N, Markowitz S,
Willson JK, Kinzler KW and Vogelstein B: Paradoxical inhibition of
solid tumor cell growth by bcl2. Cancer Res. 54:3714–3717.
1994.PubMed/NCBI
|
|
29
|
O'Reilly LA, Huang DC and Strasser A: The
cell death inhibitor Bcl-2 and its homologues influence control of
cell cycle entry. Embo J. 15:6979–6990. 1996.PubMed/NCBI
|
|
30
|
Chen L, Park SM, Tumanov AV, et al: CD95
promotes tumour growth. Nature. 465:492–496. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang Q, Li F, Liu X, et al: Caspase
3-mediated stimulation of tumor cell repopulation during cancer
radiotherapy. Nat Med. 17:860–866. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hui L, Zatloukal K, Scheuch H, Stepniak E
and Wagner EF: Proliferation of human HCC cells and chemically
induced mouse liver cancers requires JNK1-dependent p21
downregulation. J Clin Invest. 118:3943–3953. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang C, Davis JL, Zeng R, et al:
Antagonism of inhibitor of apoptosis proteins increases bone
metastasis via unexpected osteoclast activation. Cancer Discov.
3:212–223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lippitz BE: Cytokine patterns in patients
with cancer: a systematic review. Lancet Oncol. 14:e218–e228. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang RA, Li QL, Li ZS, et al: Apoptosis
drives cancer cells proliferate and metastasize. J Cell Mol Med.
17:205–211. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fidler IJ: Macrophages and metastasis - a
biological approach to cancer therapy. Cancer Res. 45:4714–4726.
1985.PubMed/NCBI
|
|
37
|
Prehn RT and Prehn LM: Cancer
immunotherapy by immunosuppression. Theor Biol Med Model. 7:452010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Thompson CB: Rethinking the regulation of
cellular metabolism. Cold Spring Harb Symp Quant Biol. 76:23–29.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bonuccelli G, Tsirigos A, WhitakerMenezes
D, et al: Ketones and lactate ‘fuel’ tumor growth and metastasis:
Evidence that epithelial cancer cells use oxidative mitochondrial
metabolism. Cell Cycle. 9:3506–3514. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Estrella V, Chen T, Lloyd M, et al:
Acidity generated by the tumor microenvironment drives local
invasion. Cancer Res. 73:1524–1535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ibrahim HA, Cornnell HH, Coelho RML, et
al: Reduction of metastasis using a non-volatile buffer. Clin Exp
Metastasis. 28:841–849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ebos JM, Lee CR, CruzMunoz W, Bjarnason
GA, Christensen JG and Kerbel RS: Accelerated metastasis after
short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell. 15:232–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
PaezRibes M, Allen E, Hudock J, et al:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell.
15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhu XD, Sun HC, Xu HX, et al:
Antiangiogenic therapy promoted metastasis of hepatocellular
carcinoma by suppressing host-derived interleukin-12b in mouse
models. Angiogenesis. 16:809–820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang WQ, Liu L, Sun HC, et al: Tanshinone
IIA inhibits metastasis after palliative resection of
hepatocellular carcinoma and prolongs survival in part via vascular
normalization. J Hematol Oncol. 5:692012. View Article : Google Scholar : PubMed/NCBI
|
